Control Resonant lifts Remedy’s quarterly revenue 226% to €39.6m, with a first operating profit since Q1

Remedy’s third-quarter revenue jumped 226% to €39.6m (from €12.2m a year earlier) after Control Resonant launched on 24 September. The numbers come from the Finnish studio’s Q3 business review, published on 3 November, which also shows a €0.6m operating profit against a €16.4m loss in the same quarter of 2025. Eurogamer was among the first to pick up the story.

The quarter captures only a sliver of the game’s life. Remedy says the figure covers pre-orders and the first seven days of sales, and CEO Jean-Charles Gaudechon called the launch “a defining milestone for the company”. It’s Remedy’s first self-published game of this scale on its own IP, and the studio says it passed one million copies sold on 15 October, the day the physical edition arrived. That makes it the fastest-selling game in Remedy’s history, a claim that comes from the company itself.

Why the profit swing looks bigger than it is

The jump from a €16.4m loss to a €0.6m profit isn’t all Control Resonant. Remedy’s review notes that Q3 2025 carried a €14.9m non-cash impairment on FBC: Firebreak, which accounts for much of the gap. Even so, the new quarter’s EBITDA of €6.8m is a clear step up from €0.7m, and the operating margin reached 1.5%.

Self-publishing also moves costs onto Remedy’s books. Revenue-related partner expenses, which include Annapurna’s share of Control Resonant revenue and platform fees, climbed to €18.9m from €0.6m. Other operating expenses rose by €5.4m to €8.0m because, as Remedy puts it, the campaign was the largest marketing investment in its history and peaked around launch. Depreciation of the game’s capitalised development costs also started. According to the company, those royalty expenses will fall once the initial investments have been recouped, and an Investing.com summary of the earnings call says a significant part of that investment hadn’t been paid back by the end of Q3.

Cash lags the headline. Operating cash flow was -€0.1m because trade and other receivables jumped to €27.7m from €8.4m, reflecting game sales that will be paid in later periods. Cash and liquid investments stood at €24.1m on 30 September, down from €36.5m a year earlier.

Who bought it

The US was the biggest market on both PC and console, accounting for nearly half of all sales by revenue and units. On PC, Chinese-speaking regions and the UK ranked second and third. On console, the UK and Canada followed the US, while Brazil also made the top three by console units. Remedy credits its first large-scale outreach to Asia and Latin America for part of that spread.

Remedy’s analytics show close to 50% of players were new to the Control series, which the studio calls a key goal for the game. Outstanding wishlists stand at 2.4m. The original Control also benefited: its Q3 sales beat the same quarter last year and each of the first two quarters of 2026, helped by promotions that ran before the sequel’s launch.

Reception backs up the sales story. Remedy cites a Metacritic score of 83, a user score of 8.8/10 and a 91% positive Steam rating, all as of 2 November.

What comes next

Gaudechon says the priority now is getting Control Resonant “into the hands of more players”, and that sales over the rest of the year will define Remedy’s 2026 result. The full-year outlook is unchanged: revenue and EBITDA are expected to rise from 2025. Nine-month revenue of €62.9m already exceeds the €59.5m reported for all of 2025, though the nine-month operating result is still a €2.3m loss.

Elsewhere in the pipeline, the Rockstar-published Max Payne 1&2 remake is in full production, and an unnamed self-published project has reached production readiness. Alan Wake had a quieter quarter, while FBC: Firebreak still earns mainly through subscription-service deals at a lower revenue level than earlier in its life.